CN1838885A - 治疗皮肤的疮和损害的方法 - Google Patents

治疗皮肤的疮和损害的方法 Download PDF

Info

Publication number
CN1838885A
CN1838885A CNA2004800242467A CN200480024246A CN1838885A CN 1838885 A CN1838885 A CN 1838885A CN A2004800242467 A CNA2004800242467 A CN A2004800242467A CN 200480024246 A CN200480024246 A CN 200480024246A CN 1838885 A CN1838885 A CN 1838885A
Authority
CN
China
Prior art keywords
composition
honey
bee product
described method
caffeine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800242467A
Other languages
English (en)
Inventor
吉尔伯特·C·吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1838885A publication Critical patent/CN1838885A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • A61K35/64Insects, e.g. bees, wasps or fleas
    • A61K35/644Beeswax; Propolis; Royal jelly; Honey
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Abstract

本发明涉及用于局部治疗皮肤的疮、损害、溃疡或其他病症的组合物,所述组合物包括蜂产品和咖啡因的组合。蜂产品可包括蜂花粉、蜂胶、蜂蜜或蜂王浆。所述组合物的变体可含有单宁。该组合物可以是对身体受感染的区域局部施用的软膏剂或霜剂的形式。该组合物还可以其他如喷雾剂、洗发剂、皂、唇膏或粘性绷带的形式施用。本发明还可用作保健型饮料。

Description

治疗皮肤的疮和损害的方法
技术领域
本发明总地涉及治疗疮(sores)和皮肤损害(lesions)的方法,更具体地,本发明涉及治疗与单纯疱疹病毒有关的疮和损害。
背景技术
单纯疱疹病毒(HSV)是引起皮肤和粘膜感染的常见原因。HSV是最难以控制的病毒之一并且数千年来人们一直受其困扰。HSV感染通常表现为口或脸疼痛水疱样损害或疮(口疱疹)、或生殖器区域内的疼痛水疱样损害或疮(生殖器疱疹)。虽然疱疹疮很少致命,但疱疹疮可以是相当疼痛并且难看的,并且可引起感染者的困窘。
有两种不同类型的单纯疱疹病毒,单纯疱疹病毒1型(HSV-1)和单纯疱疹病毒2型(HSV-2)。HSV-1和HSV-2非常相似。它们可独立地发生或可感染同一个体。HSV-1通常与口疱疹有关,HSV-2通常与生殖器疱疹有关。然而,还未知HSV-2可引起口疱疹以及HSV-1可引起生殖器疱疹。
HSV在与被感染的人接触后通过皮肤或粘膜进入人体。病毒侵入皮肤下层中易受攻击的细胞并试图在细胞核中进行自身复制。在许多病例中,HSV从不引发症状的产生。然而,如果HSV的复制过程破坏了宿主细胞,则可出现各种形式的症状:疮、溃疡和充满液体的水疱。来自原发感染的疮最终愈合而不形成疤痕。然而,引发感染的病毒留在体内并移动通过神经细胞分枝到达神经细胞末端处的集簇(称作神经节)。病毒继续在神经节中保留一定的潜伏期,在此期间不发生病毒复制。当病毒处于潜伏期时,不出现病毒的症状。在潜伏一定时间后,病毒可能再次开始复制,引起反复感染。HSV的反复感染较原发感染温和,并可以由各种因素触发,所述因素包括生病和压力。对于一些感染了疱疹病毒的人,可能频繁发生反复感染。约20-40%有HSV-1感染史的人经历反复发病。对于感染HSV-2的人,反复感染率高达80%。
科学家们正接近于解开疱疹病毒的遗传结构。然而目前尚不能治愈疱疹。因此,仍然需要新的药物和疗法以改善HSV反复发病的症状。
发明概述
本发明包括用于治疗皮肤的疮、溃疡、损害或其他病症的局部用药物组合物。已经发现该组合物有效治疗与单纯疱疹病毒有关的疮。该组合物还可用于治疗由病毒感染引发的鸡痘(chicken pox)、带状疱疹或其他皮肤病症。
所述组合物的活性成分包括蜂产品和咖啡因的组合。蜂产品可包括例如蜂蜜、蜂胶、蜂花粉或蜂王浆。所述组合物的变体还可包括单宁作为活性成分。组合物可为对皮肤进行局部施用的霜剂、软膏剂或凝胶剂的形式。该组合物还可以其他形式使用,如喷雾剂、洗发剂、皂、唇膏或粘性绷带的形式。本发明还可用作保健型饮料。
发明详述
本发明包括用于局部施用于皮肤的组合物,该组合物包括蜂产品和咖啡因的组合作为活性成分。蜂产品可包括例如蜂蜜、蜂胶、蜂花粉或蜂王浆。由于科学家对组合物如何对抗HSV有了更好的了解,因此本发明的组合物可由提取自蜂蜜或其他蜂产品的活性成分形成、或由合成的与蜂蜜或蜂产品中所述活性成分相似的活性成分形成。因此,本文使用的术语蜂产品包括提取自蜂产品的活性成分、和合成的与蜂产品中所述活性成分相似的活性成分。本发明组合物的变体还可包括单宁作为活性成分。
在一个示例性实施方案中,制备了包括蜂蜜(优选未经加工的)和咖啡末(coffee grounds)的油膏剂。该油膏剂通过将约一大汤匙咖啡末与足以使咖啡末不散开的蜂蜜混合制备而成。据估计,该油膏剂包括约15重量%的蜂蜜。通过将油膏剂敷开在疮处并用绷带覆盖疮处而将所述油膏剂施用于一个患者的由单纯疱疹病毒1型引起的疮处。对疮施用油膏剂后,在3-4小时内疮显著减小,在2天内疮完全愈合。在用抗HSV组合物治疗前,该患者一个月内经历1-2次反复感染。在治疗后,该患者在多于5个月之后未发生一次感染复发。
本发明的组合物可使用美国专利5,382,436中所述的微粉化咖啡因粒子进行制备,所述专利并入本文作为参考。需要进一步的研究以确定咖啡因和蜂产品的最有效的量。目前,本发明人相信含有大于1重量%咖啡因的组合物将是有效的。
蜂蜜的粘性使得其不便于局部施用。因此,组合物除了活性剂之外可包括可药用赋形剂。可使用添加剂如油类、增稠剂和乳化剂以形成更适合局部施用的软膏剂、霜剂、洗液或凝胶剂。可用的天然油类的例子包括玉米油、杏仁油、橄榄油、椰子油、蓖麻油和羊毛脂油。还可使用合成油类如硅油。可用的增稠剂包括天然蜡类如蜂蜡、石蜡和烃类聚合物。美国专利6,171,604,其被并入本文作为参考,公开了各种局部用蜂蜜基制剂。在该专利中所述的制剂可用于本发明中。
组合物可制成局部施用于皮肤的软膏剂、霜剂、油膏剂、洗液或凝胶剂。该组合物还可以如喷雾剂、洗发剂、皂或唇膏的其他形式使用。本发明的另一个应用是可施用于皮肤的具有吸收垫的粘性绷带。咖啡因和蜂蜜的混合物也可用在可被摄食的保健型饮料中。饮料可用于预防HSV或其他疾病的发病,或者可被摄食以减小发病的影响。
还不知道组合物抑制HSV感染的机理。咖啡因与腺苷非常相似,并且将与腺苷受体结合。可能是咖啡因与HSV所使用的病毒受体结合,从而抑制HSV复制。已知蜂花粉、蜂胶和蜂蜜具有抗氧化性、抗生素活性和抗真菌活性。在过去,蜂产品已经作为家庭疗法用于创伤、复发性口疮、口溃疡和疱疹的治疗。存在于蜂蜜中的蜂胶含有咖啡酸苯乙酯(CAPE)。过去的研究表明CAPE抑制癌细胞的生长,因此可用作抗肿瘤药。在实验室培养中,蜂胶已显示出抑制包括疱疹病毒和流感病毒在内的某些病毒的生长。单宁是天然存在的植物多酚,其与蛋白质和其他聚合物结合形成稳定的化合物。已知某些单宁具有防腐活性、抗生素活性和抗病毒活性。相对高浓度的单宁可抑制酶的活性。某些单宁还表现出强的抗肿瘤活性。
近些年来,联合治疗在抗HSV治疗中越来越普遍,并有研究表明某些药物可增强其他药物的药效,产生附加作用或协同作用。已知可有效用于疱疹治疗的联合治疗包括三氟胸苷(TFT)与干扰素α、咖啡因与干扰素、以及二甲基亚砜(DMSO)和碘苷(IDU)。据推测蜂产品和咖啡因的组合与使用单独的咖啡因或蜂产品进行治疗相比具有协同抑制病毒复制的作用。单宁还可起到使蜂蜜和咖啡因中的活性成分保留在皮肤下层中的作用,以防止HSV复发。
所述组合物可用于治疗由单纯疱疹病毒引起的疮和损害,并可用于治疗鸡痘、带状疱疹或其他病毒感染。

Claims (26)

1.用于局部治疗皮肤的疮、损害、溃疡和其他病症的组合物,所述组合物包括以下a)和b)的组合:
a)蜂产品;和
b)咖啡因。
2.权利要求1所述的组合物,其中所述蜂产品包括蜂蜜。
3.权利要求1所述的组合物,其中所述组合物包括约15重量%的蜂蜜。
4.权利要求1所述的组合物,其中所述蜂产品包括蜂胶。
5.权利要求1所述的组合物,其中所述蜂产品包括蜂花粉。
6.权利要求1所述的组合物,其中所述蜂产品包括蜂王浆。
7.权利要求1所述的组合物,另外包括单宁。
8.权利要求1所述的组合物,为施用于皮肤的霜剂、软膏剂或油膏剂的形式。
9.权利要求1所述的组合物,为施用于皮肤的凝胶剂的形式。
10.权利要求1所述的组合物,为液体或喷雾剂的形式。
11.权利要求1所述的组合物,为唇膏的形式。
12.治疗皮肤的疮、损害、溃疡或其他病症的方法,包括:
a)对皮肤受感染的区域局部施用含有有效量的蜂产品和咖啡因的组合物。
13.权利要求12所述的方法,其中所述蜂产品包括蜂蜜。
14.权利要求12所述的方法,其中所述组合物包括约15重量%的蜂蜜。
15.权利要求2所述的方法,其中所述蜂产品包括蜂胶。
16.权利要求12所述的方法,其中所述蜂产品包括蜂花粉。
17.权利要求12所述的方法,其中所述蜂产品包括蜂王浆。
18.权利要求12所述的方法,其中所述组合物另外包括单宁。
19.权利要求12所述的方法,其中所述组合物以软膏剂、洗液或油膏剂的形式施用。
20.权利要求12所述的方法,其中所述组合物以凝胶剂的形式施用。
21.权利要求12所述的方法,其中所述组合物以液体或喷雾剂的形式施用。
22.权利要求12所述的方法,其中所述组合物以唇膏的形式施用。
23.治疗病毒感染的方法,包括:
a)制备咖啡因和蜂蜜的混合物;和
b)用所述咖啡因-蜂蜜混合物治疗所述病毒。
24.权利要求23所述的方法,其中通过对疮处局部施用所述咖啡因-蜂蜜混合物治疗病毒。
25.权利要求23所述的方法,其中通过饮用含有所述咖啡因-蜂蜜混合物的饮料治疗病毒。
26.权利要求23所述的方法,其中病毒为单纯疱疹病毒。
CNA2004800242467A 2003-06-23 2004-06-22 治疗皮肤的疮和损害的方法 Pending CN1838885A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/602,404 US20040258765A1 (en) 2003-06-23 2003-06-23 Method for treatment of sores and lesions of the skin
US10/602,404 2003-06-23

Publications (1)

Publication Number Publication Date
CN1838885A true CN1838885A (zh) 2006-09-27

Family

ID=33518088

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800242467A Pending CN1838885A (zh) 2003-06-23 2004-06-22 治疗皮肤的疮和损害的方法

Country Status (6)

Country Link
US (2) US20040258765A1 (zh)
EP (1) EP1643846A4 (zh)
CN (1) CN1838885A (zh)
AU (1) AU2004251720B2 (zh)
CA (1) CA2533591C (zh)
WO (1) WO2005000032A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3939C2 (ro) * 2009-01-28 2010-04-30 Виктор УСАТЕНКО Unguent antimicrobian pe bază de produse apicole (variante)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US7893070B2 (en) 2005-08-15 2011-02-22 Provimi Holding B.V. Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
BRPI0615204A2 (pt) * 2005-08-15 2013-01-08 Provimi Holding B V uso de um estimulante psicomotor, composiÇço na forma de uma pasta ou um gel, e, kit
US20110142957A1 (en) * 2005-08-15 2011-06-16 Van Kempen Theo Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
US20070098671A1 (en) * 2005-11-02 2007-05-03 Martin Gregory D Composition and method of treatment for irritated skin
US20080167277A1 (en) * 2006-12-29 2008-07-10 Charles Conrad Methods of treating skin disorders with caffeic acid analogs
US8241683B2 (en) * 2007-04-16 2012-08-14 Kikuji Yamaguchi Decolonizing agent for helicobacter pylori
US20100074964A1 (en) * 2008-03-10 2010-03-25 Zdenko Glavas Super brown cream
US20090226483A1 (en) * 2008-03-10 2009-09-10 Zdenko Glavas Super brown cream
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
GB2471504A (en) * 2009-07-02 2011-01-05 Paul Myott Caffeine for use in the healing of damaged skin, body tissue, muscles, organs and hair
EP2921187B1 (en) 2009-11-17 2018-03-21 Brightwake Limited Device and method for processing fluid
CN103083424A (zh) * 2013-01-21 2013-05-08 徐雪云 一种治疗小儿疱疹性口炎的中药制剂
WO2015028892A2 (en) 2013-08-12 2015-03-05 Decima Health Limited Reaction platform and method for making pollen based materials in combination with beeswax and uses thereof
US10434123B2 (en) 2013-08-12 2019-10-08 Decima Health Limited Reaction platform and method for making pollen based materials and uses thereof
CA2931564C (en) * 2013-11-25 2022-08-30 Dermal Devices Inc. Composition, system and method for treating skin
US10232048B1 (en) 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
GR1009175B (el) 2016-06-13 2017-12-18 Apivita Καλλυντικα Διαιτητικα Φαρμακα Ανωνυμη Εμπορικη Και Βιοτεχνικη Εταιρεια Συνδυασμος εκχυλισματος μικροφυκους nannochloropsis gaditana και εκχυλισματος προπολης ως δραστικου συστατικου σε καλλυντικοτεχνικες φορμουλες για δερματικη χρηση
CN107496636A (zh) * 2017-10-21 2017-12-22 马有奎 治疗带状疱疹的中药组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285934A (en) * 1979-07-13 1981-08-25 Tinnell James E Treatment for herpes virus
US4382886A (en) * 1981-04-13 1983-05-10 Sosnowski Zenon M Method for extracting propolis and water soluble dry propolis powder
GB8926595D0 (en) * 1989-11-24 1990-01-17 Surtech Int Ltd Pharmaceutical compositions for use in the treatment herpes simplex virus infections
US5620724A (en) * 1993-07-26 1997-04-15 Adler; Richard S. Drink container with holder for used concentrate packet
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5980875A (en) * 1996-04-12 1999-11-09 Mousa; Mahmoud A. Honey preparations
US5900226A (en) * 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
TW587943B (en) * 1998-01-13 2004-05-21 Kose Corp Powder composition, a powder dispersion in oil and a cosmetic composition containing said powder composition and a powder dispersion in oil
US6190680B1 (en) * 1998-04-01 2001-02-20 The Nisshin Oil Mills, Ltd. Oily composition and process for producing the same
US6524625B2 (en) * 1998-06-30 2003-02-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuto Physiologically active extract obtained from indigo plant polygonum tinctorium
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7288265B1 (en) * 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
US7396546B2 (en) * 2001-08-06 2008-07-08 The Quigley Corporation Anti-microbial compositions and methods of using same
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3939C2 (ro) * 2009-01-28 2010-04-30 Виктор УСАТЕНКО Unguent antimicrobian pe bază de produse apicole (variante)

Also Published As

Publication number Publication date
US9387227B2 (en) 2016-07-12
WO2005000032A1 (en) 2005-01-06
AU2004251720A1 (en) 2005-01-06
CA2533591A1 (en) 2005-01-06
US20150374759A1 (en) 2015-12-31
EP1643846A1 (en) 2006-04-12
EP1643846A4 (en) 2009-06-24
AU2004251720B2 (en) 2009-01-08
CA2533591C (en) 2012-11-06
US20040258765A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
US9387227B2 (en) Method for treatment of sores and lesions of the skin
ES2278393T3 (es) Tratamiento antimicrobiano del virus herpes simplex y otras enfermedades infecciosas.
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
EP0954278A1 (en) Pharmaceutical compositions containing kukui nut oil
US20080031979A1 (en) Use of extracts for the treatment of viral disorders
US20090220440A1 (en) Spray Composition for Topical Use for Treating and/or Preventing Herpes Simplex Labial Infections
NZ565003A (en) Composition for treating skin lesions
CN102458156A (zh) 含有栗子皮提取物的健康食品或药学组合物
US10052328B2 (en) Therapeutic composition to treat lesions caused by Herpes Simplex Virus
WO2011069184A1 (en) Composition for treating skin lesions
CN110664858B (zh) 一种用于皮肤的青蒿提取物组合物、产品及其应用
JP2000512270A (ja) 単純ヘルペスの処置のための組成物および方法
WO2005002608A1 (en) Herbal composition
US5382436A (en) Caffeine in the treatment of Herpes simplex virus infections
JPH07508010A (ja) DNAウイルス感染の治療のための薬物の製造のための膜翅類昆虫(hymenoptera)毒の使用
WO2011035120A2 (en) Therapeutic composition to treat lesions caused by herpes simplex virus
US5977176A (en) Compositions for the treatment of warts and herpes
AU2009217410B2 (en) Composition for treating skin lesions
RU2241443C1 (ru) Фармацевтическая композиция для лечения герпес-вирусной инфекции
US8492443B2 (en) Treatment for herpes simplex virus and other infectious diseases
KR101679978B1 (ko) 자단향 추출물을 유효성분으로 함유하는 알레르기성 질환 예방 또는 치료용 피부외용제
EP3013330A1 (en) Anti-viral compound and composition
CA2591352A1 (en) Treatment for herpes simplex virus and other infectious diseases
MXPA98009256A (en) Antimicrobial treatment for herpes simplex virus and other infectious diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1094756

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060927

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1094756

Country of ref document: HK